ARTICLE | Product Development
Data from Merck, Daiichi could support first approval for HER3 ADC
In BioCentury’s latest clinical report, Merck-Daiichi product scores on PFS after setback at FDA, plus updates from Ascendis, Boehringer, Atea and more
September 18, 2024 1:26 AM UTC
New progression-free survival results from the Phase III HERTHENA-Lung02 study add to the body of evidence that could support the first approval of patritumab deruxtecan (HER3-DXd).
The antibody-drug conjugate from Merck & Co. Inc. (NYSE:MRK) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) led to a significant improvement in progression-free survival (PFS) compared with chemotherapy, meeting the trial’s primary endpoint, among patients with EGFR-mutant non-small cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitor treatment...
BCIQ Company Profiles